361 Capital’s Meridian Bioscience Inc VIVO Stock Holding History

361 Capital’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-23,988	Closed	-$378K	–	304
2017 Q2	$378K	Buy	+23,988	New	+$346K	0.06%	152

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

361 Capital's VIVO Position: Q3 2017 in Review

361 Capital sold out of Meridian Bioscience Inc (VIVO) in Q3 2017, closing a stake of 23,988 shares — an estimated $378K sold.

361 Capital first reported a position in VIVO in Q2 2017 and held it in 1 quarter. The position peaked at $378K in Q2 2017. 172 funds tracked by Wall St. Rank hold VIVO as of Q3 2017.

361 Capital reported no remaining Meridian Bioscience Inc position as of Q3 2017 after selling out during the quarter.
361 Capital sold 23,988 Meridian Bioscience Inc shares in Q3 2017, an estimated $378K.
361 Capital first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 1 quarter.
361 Capital's Meridian Bioscience Inc position peaked at $378K in Q2 2017.
172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2017.

Based on 361 Capital's 13F filing for Q3 2017, filed 7 Nov 2017.